SCHEMBL97681

SCHEMBL97681

[CH2]c1ccc(CCCC)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.54
CA1 P00915 1/20 0.54
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 2/20 0.52
HPGD P15428 1/20 0.52
ESR1 P03372 2/20 0.50
ADRA2A P08913 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
TACR2 P21452 2/20 0.50
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.50
SLC6A3 Q01959 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
THRA P10827 1/20 0.50
THRB P10828 1/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
SHBG P04278 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27887291 0.98 CA2 (0.52) CA2CA1ALDH1A1HSD17B10HPGD
SCHEMBL27862855 0.93 RARB (0.56) CA2CA1ALDH1A1HSD17B10HPGD
SCHEMBL1101345 0.93 ESR1 (0.59) CA2ALDH1A1HSD17B10ESR1ADRA2A
Magnesium Chloride Anhydrous SCHEMBL27534583 0.91 HTR2A (0.48) CA2CA1ALDH1A1HSD17B10HPGD
SCHEMBL23755035 0.91 ESR1 (0.63) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL7335623 0.91 ESR1 (0.63) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL23754712 0.91 ESR1 (0.63) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL1119534 0.91 ESR1 (0.63) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL7929651 0.91 ESR1 (0.63) ALDH1A1HSD17B10ESR1ADRA2AADORA3
SCHEMBL1006220 0.91 ESR1 (0.63) ALDH1A1HSD17B10ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106588696-A Preparation method of trans-alpha, beta-unsaturated nitriles compound 西北师范大学 2017-04-26 CN claimed
US-20150232420-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF EVOTEC (UK) LTD. (GB) 2015-08-20 US claimed
EP-2486005-B1 PYRROLIDINE GPR40 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP claimed
US-8288404-B2 Pyrrolidine GPR40 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-16 US claimed
EP-2486005-A1 PYRROLIDINE GPR40 MODULATORS Bristol-Myers Squibb Company (US) 2012-08-15 EP claimed
CN-102584829-A Pyrazole and pyrazine diketone derivative and application thereof UNIV SHANDONG 2012-07-18 CN claimed
US-7947837-B2 dimeric and polymeric compounds based upon fused ring tetracarboxylic imides, used as electronic thin films on substrates; transistors POLYERA CORPORATION (US) 2011-05-24 US claimed
WO-2011044073-A1 PYRROLIDINE GPR40 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-14 WO claimed
US-20110082165-A1 PYRROLIDINE GPR40 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-04-07 US claimed
CN-101367819-B 5-substituent-2-(4-substituted phenyl)-6,7-dihydrogen pyrazole-[1,5-a]pyrazine-4(5H)-ketone derivant and uses thereof UNIV SHANDONG 2010-08-18 CN claimed
EP-1307198-A1 PROTOBERBERINE DERIVATIVES WHICH INHIBIT ACTIVITY OF THE MITOGEN-ACTIVATED PROTEIN KINASE HANWHA CHEMICAL CORPORATION (KR) 2003-05-07 EP claimed
US-6410497-B1 DETERGENTS; BLEACHES; ANTISEPTICS BASF AKTIENGESELLSCHAFT (DE) 2002-06-25 US claimed
US-20020052501-A1 4-cyanocoumarin derivatives and uses thereof KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2002-05-02 US claimed
WO-2001095908-A1 PROTOBERBERINE DERIVATIVES WHICH INHIBIT ACTIVITY OF THE MITOGEN-ACTIVATED PROTEIN KINASE HANWHA CHEMICAL CORPORATION (KR) 2001-12-20 WO claimed
EP-1041074-A1 Light-sensitive 4-cyanocoumarin derivatives KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2000-10-04 EP claimed
US-5510519-A OPTICAL RESOLUTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-04-23 US claimed
EP-0508307-B1 Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound SUMITOMO CHEMICAL CO (JP) 1995-11-29 EP claimed
US-5298660-A Compound containing an assymetrical carbon atom SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1994-03-29 US claimed
EP-0508307-A2 Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1992-10-14 EP claimed
US-4681699-A Bisazo dyes and their use in liquid crystalline materials BASF AKTIENGESELLSCHAFT (DE) 1987-07-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232420-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF HTT, TGM2, GRN CA2 478/4885CA1 475/4885ALDH1A1 3161/4885
US-20020052501-A1 4-cyanocoumarin derivatives and uses thereof CACYBP, CYBA, IK CA2 548/4885CA1 1817/4885ALDH1A1 1333/4885
US-20110082165-A1 PYRROLIDINE GPR40 MODULATORS GPR55, GPR65, GPR27 CA2 1527/4885CA1 4429/4885ALDH1A1 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.